Clinical trials: Hepatic Neoplasm
HCC - Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
This is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.
- Trial name
- Neo-LENTIS (NCT07475026)
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Cirrhosis, Hepatocellular Carcinoma
Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related deaths worldwide. The incidence of HCC has been rapidly rising worldwide over the last two decades.
- Trial name
- NCT06312826
- Testing
- Abdominal US, AMRI
- Where
- South Korea
- Volunteers
- 806 people
- Sponsor
- Asan Medical Center
Carcinoma, Hepatocellular
Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas
Micronecrosis is a novel pathological feature of hepatocellular carcinoma (HCC). This study was aimed at evaluating the effect of tumor micronecrosis on postoperative transcatheter arterial chemoembolization (TACE) in patients…
- Trial name
- NCT05352204
- Testing
- transcatheter arterial chemoembolization
- Where
- 2 sites in China
- Volunteers
- 900 people
- Sponsor
- Zhejiang University
Hepatitis C, Hepatocellular Carcinoma
Direct Acting Antiviral-Post Authorization Safety Study
This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting…
- Trial name
- NCT03707080
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Target PharmaSolutions, Inc.
Hepatocellular Carcinoma
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria
- Trial name
- NCT03775707
- Testing
- Lenvatinib, PD-1 antibody
- Where
- China
- Sponsor
- Shi Ming
Advanced Solid Malignancies
A Study of MEDI-575 in Patients With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).
- Trial name
- NCT01102400
- Testing
- MEDI-575
- Where
- 5 sites in Japan
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma (HCC) Prognosis, Contrast-enhanced Ultrasound
A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide, with a significantly increased incidence among patients with liver diseases.
- Trial name
- NCT07600346
- Testing
- Contrast-Enhanced Ultrasound
- Volunteers
- 105 people
- Sponsor
- The First Hospital of Jilin University
Hepatocellular Carcinoma, Liver Cancer
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Localized Unresectable Liver Cancer
- Trial name
- NCT01042041
- Testing
- sorafenib tosylate, doxorubicin hydrochloride, cisplatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Liver Cancer
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by hepatic artery versus vein infusion of…
- Trial name
- NCT03949231
- Testing
- PD1/PDL1 inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Resectable Hepatocellular Carcinoma
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
- Trial name
- NCT07446257
- Testing
- ateganosine, Cadonilimab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Carcinoma, Liver Cancer
TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma
The purpose of this study is to prospectively evaluate whether transcatheter arterial chemoembolization (TACE) will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC) or not.
- Trial name
- TACE-RFA (NCT00556803)
- Testing
- radiofrequency ablation, TACE after RFA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized…
- Trial name
- OPTIMA (NCT02112656)
- Testing
- ThermoDox, Dummy infusion
- Where
- 61 sites in United States, Canada and 12 more
- Volunteers
- 554 people
- Sponsor
- Imunon
Hepatocellular Carcinoma, HCC
Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
The incidence of hepatocellular carcinoma (HCC) has recently increased in the United States. Although imaging plays a major role in HCC screening and staging, the possibility of predicting HCC tumor grade, aggressiveness…
- Trial name
- NCT01871545
- Testing
- Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatocellular Carcinoma
The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients
Hepatocellular carcinoma (HCC) is the most prominent kind of liver cancer, accounting for 85% of primary liver malignancies. It is a very aggressive tumor, having a terrible prognosis and poor survival rate HCC is ranked as the…
- Trial name
- NCT06328283
- Testing
- measure of Glutamine synthetase and BCLFAF1
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Sohag University
Hepatic Neoplasms
Identification of Hepatic Lesions
Patients with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment.
- Trial name
- NCT00307866
- Testing
- Resovist (BAY86-4884, SH U 555 A)
- Where
- 19 sites in Italy
- Volunteers
- 218 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with hepatocellular…
- Trial name
- NCT03468231
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Liver Cancer
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
The primary objective will be to assess progression-free survival (PFS) measured at 16 weeks following initiation of therapy with the combination of Avastin and erlotinib in patients with unresectable hepatocellular carcinoma…
- Trial name
- NCT00242502
- Testing
- Bevacizumab (Avastin), Erlotinib
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Bronchial Cancer
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
24 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory advanced solid tumors.
- Conditions
- Lung Cancer, Bronchial Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT05886075
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Yunying Medical Technology
Hepatocellular Carcinoma
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
The purpose of this study is to investigate the efficacy and safety of lenvatinib plus nivolumab compared with lenvatinib monotherapy for patients with advanced hepatitis B virus infection-related hepatocellular carcinoma.
- Trial name
- NCT04044651
- Testing
- Lenvatinib, Nivolumab
- Where
- 5 sites in China
- Sponsor
- Shi Ming
Liver Cirrhosis, Hepatocellular Carcinoma
Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma
In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Surveillance
- Trial name
- NCT04414956
- Testing
- AFP-L3, AFP, PIVKA-II
- Where
- 15 sites in South Korea
- Volunteers
- 1,418 people
- Sponsor
- Korea University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.